These results may suggest that, despite clinicopathological and prognostic differences between conventional and unicystic ameloblastomas, the BRAF V600E mutation could be a significant event also in the pathogenesis of unicystic ameloblastomas. This evidence concerns the gene BRAF and ameloblastoma.